Fetal Screening


Fetal RHD screening test

(only available to customers in the UK and Ireland – a service-specific contract is required) 

We offer a United Kingdom Accreditation Service (UKAS) accredited fetal RHD screening service to prevent unnecessary administration of anti-D prophylaxis. The test predicts fetal RhD status with high accuracy from a sample of maternal blood and will improve care for RhD-negative women in the UK and the Republic of Ireland by reducing the need to administer a blood product to healthy pregnant women.

IBGRL have optimised and automated the testing technology applied to pregnancies at risk of haemolytic disease of the fetus and new-born (HDFN) to enable high throughput fetal RHD screening of all D negative pregnant women, who have not formed immune anti-D or anti-G to guide antenatal anti-D prophylaxis. 

High-throughput non-invasive prenatal testing for fetal RHD genotype is recommended by the National Institute for Health and Care Excellence (NICE) as a cost-effective option to guide antenatal prophylaxis with anti-D immunoglobulin.

For further information about the fetal RHD screening test, please read our brochure.

This is not a diagnostic test for fetal RhD status for women who have made anti-D (or-G). Please refer to the management of pregnant women with alloantibodies.

Investigation Notes Samples required Accompanying form Turnaround times
Fetal RHD screening test Requires contract Minimum of 6mL EDTA blood FRM5197 (PDF 109KB)

FRM5197 Guidance (PDF 429KB)

Within 10 business days

More information about our services

User guide

Download our user guide for referring samples to IBGRL Molecular Diagnostics

Download guide (PDF 421KB)

Have a question?

Please contact the laboratory or our business development manager for more information:

If you wish to set up a contract to send samples or would like to obtain information regarding the tests performed, please contact Erika Rutherford.

For all other enquiries, please contact Molecular Diagnostics.